Here's What to Expect From Biogen's Next Earnings Report Biogen is expected to release its fiscal second-quarter earnings later this month, and analysts project a double-digit profit decline. Barchart · Jul 18, 2025
Is Biogen Stock Underperforming the S&P 500? Biogen has significantly underperformed the S&P 500 over the past year, but analysts are moderately optimistic about the stock’s prospects. Barchart · Jun 12, 2025
Do Wall Street Analysts Like Biogen Stock? Biogen has significantly underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects. Barchart · May 20, 2025
Earnings Preview: What To Expect From Biogen's Report Biogen is poised to announce its first-quarter results next month, and analysts predict a single-digit dip in the company’s bottom-line figure. Barchart · Apr 21, 2025
How Is Biogen's Stock Performance Compared to Other Biotech Stocks? Despite Biogen's underperformance compared to other biotech stocks over the past year, analysts remain moderately optimistic about its future prospects. Barchart · Mar 19, 2025
Biogen Stock Outlook: Is Wall Street Bullish or Bearish? Biogen has lagged well behind the broader market over the past year, yet analysts maintain a fairly optimistic outlook on its future performance. Barchart · Feb 24, 2025
Biogen Stock Is Mutating Into a Value Play Biogen shares have fallen over 70% from its highs nearly 12-years ago, but value investors should take a look at its metrics of just 12.4 P/E and P/B of 1.2X MarketBeat · Feb 20, 2025
Biogen's Quarterly Earnings Preview: What You Need to Know Biogen is scheduled to release its fourth-quarter earnings next month, and analysts are forecasting a double-digit increase in its bottom line. Barchart · Jan 17, 2025
3 Biotech Stocks Innovating the Future of Medicine The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing advancements like AI. Therefore, fundamentally sound biotech stocks Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Gilead Sciences (GILD), which are at the forefront of innovation, could be ideal portfolio additions. Read more. StockNews.com · Jan 8, 2025
Biogen Stock: Is BIIB Underperforming the Healthcare Sector? Biogen has recently lagged behind the broader healthcare sector, and analysts maintain a cautiously optimistic outlook on the stock's long-term growth potential. Barchart · Dec 17, 2024
3 Biotech Stocks with Promising Pipelines to Watch As breakthroughs in biotechnology accelerate, the sector is primed for significant expansion. With emerging trends like gene editing and precision medicine transforming healthcare, fundamentally solid biotech stocks such as Amgen (AMGN), Gilead Sciences (GILD), and Biogen (BIIB) are gaining traction. With promising innovations, these stocks could be prime investment opportunities.… StockNews.com · Nov 29, 2024
Are Wall Street Analysts Predicting Biogen Stock Will Climb or Sink? Biogen has significantly underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects. Barchart · Nov 25, 2024
3 Biotech Stocks Predicted to Surge on Medical Innovation Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, investors might consider adding fundamentally strong biotech stocks like Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Gilead Sciences (GILD) to their portfolio for an impactful investment. Continue reading…. StockNews.com · Nov 6, 2024
Biogen's Q3 2024 Earnings: What to Expect Biogen will release its third-quarter earnings this month, and analysts anticipate a double-digit profit dip. Barchart · Oct 24, 2024
StockNews.com · Oct 15, 2024 3 Biotech Stocks Set to Revolutionize Medicine The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To capitalize on the industry’s expansion, it could be wise to invest in fundamentally sound biotech stocks, Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB), which have the potential to revolutionize medicine. Read…
StockNews.com · Oct 9, 2024 3 Biotech Stocks With Huge Upside Based on Analyst Price Targets The biotech sector’s long-term growth is fueled by strong government support, increasing funding and M&A activities, and rapid AI adoption. Therefore, quality biotech stocks Royalty Pharma (RPRX), BioMarin Pharmaceutical (BMRN), and Biogen (BIIB) with major upside could be ideal additions to your portfolio. Keep reading.
StockNews.com · Sep 25, 2024 3 Biotech Stocks Wall Street Predicts Will Skyrocket Biotech companies could gain the financial flexibility to accelerate their innovations with the Fed’s recent rate cut. To capitalize on this opportunity, consider investing in fundamentally sound biotech stocks Biogen (BIIB), Royalty Pharma (RPRX), and BioMarin Pharmaceutical (BMRN), that are poised to skyrocket. Learn more.
StockNews.com · Sep 24, 2024 3 Biotech Stocks That Could Deliver Big Gains The biotech industry is poised for significant growth, fueled by advanced technologies, the increased commercialization of new therapeutics, and increased R&D spending on treatments for new and rare diseases. Hence, investors should consider strong biotech stocks such as Amgen (AMGN), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB), which could deliver big…
Barchart · Sep 20, 2024 Is Biogen Stock Underperforming the Dow? Biogen has underperformed the Dow over the past year, but analysts are moderately optimistic about the stock’s prospects.
StockNews.com · Sep 14, 2024 3 Healthcare Stocks With High Analyst Price Targets Recent innovations, successful trials, and increased research and development spending in the healthcare sector further boost the sector’s appeal today. Given this momentum, investors might consider investing in stocks with high analyst price targets, such as Pfizer (PFE), Biogen (BIIB), and BioMarin Pharmaceutical (BMRN). Read on….
Barchart · Aug 20, 2024 Is Wall Street Bullish or Bearish on Biogen Stock? Despite Biogen’s underperformance relative to the broader market over the past year, Wall Street analysts remain moderately bullish about the stock’s prospects.
Barchart · Jul 18, 2024 Biogen Earnings Preview: What to Expect Biogen is expected to release its fiscal second-quarter earnings next month, and analysts project a single-digit profit dip.
Barchart · Jun 26, 2024 Is Biogen Stock Underperforming the Nasdaq? Biogen underperforms the Nasdaq Composite, and analysts remain cautiously optimistic about the stock’s prospects.
Barchart · Mar 7, 2024 5 Biotech Stocks With 26% Upside Potential or More As biotech stocks swing back into favor on Wall Street, here's a look at five picks that could deliver significant gains, according to analysts.
StockNews.com · Feb 13, 2024 Moderna (MRNA) and Biogen (BIIB) - Are There Upsides Left in These Biotech Stocks? Despite macroeconomic challenges, the biotech industry thrives on innovation, demand, adaptability, and technological advancements, demonstrating resilience. So, let’s analyze the upside potential of popular biotech stocks Biogen (BIIB) and Moderna (MRNA).